Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2017 | 09:28am CEST

(Reuters) - Hikma Pharmaceuticals Plc (>> Hikma Pharmaceuticals) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

(Reuters) - Hikma Pharmaceuticals Plc (>> Hikma Pharmaceuticals) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

The dispute between the Jordan-based firm, its partner Vectura (>> Vectura Group PLC) and the U.S FDA delays any eventual approval of the generic version of the drug.

Shares of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

Hikma, which makes and markets branded and non-branded generic and injectable drugs, said it expected revenue of around $600 million and a core operating margin in the low single-digits from its generics business.

In August it had lowered its generics revenue guidance by $50 million to about $620 million citing higher pricing pressures in the industry, having slashed it to $670 million from an initial $800 million last November.

The company, that has been hit by higher price erosion levels than the rest of the industry, has been re-negotiating its contracts with suppliers and third-party vendors to cut costs to try to boost profitability.

"We expect these market conditions to persist in 2018 and are actively pursuing new commercial opportunities and focussing on the execution of our pipeline to help offset continuing price erosion across the industry," it said in a statement.

The company, which cut its full-year guidance in May to the range of $2 billion-$2.1 billion from $2.2 billion, said in August that it expected 2017 revenue to be at the lower end of the range at $2 billion.

Hikma reiterated its 2017 revenue expectations on Thursday.

Earlier this month, Israeli-based Teva Pharmaceutical (>> Teva Pharmaceutical Industries Limited), the world's biggest generics drugmaker, said it would miss 2017 profit forecasts citing falling prices of generics in the U.S. market and weakening sales of its multiple sclerosis drug.

Hikma's lower guidance in May followed a decision by U.S. regulators not to approve its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair, citing "major" issues with the application.

Hikma said it expected the dispute process with the FDA to be completed in the first quarter of 2018.

(Reporting by Justin George Varghese in Bengaluru and Ben Hirschler in London; editing by Jason Neely and Keith Weir)

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 0.18% 1563.8 Delayed Quote.18.03%
HIKMA PHARMACEUTICALS -0.30% 1475.5 Delayed Quote.30.51%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 0.80% 8490 Delayed Quote.30.09%
VECTURA GROUP PLC 1.32% 80.5 Delayed Quote.-32.50%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
06:54pNovartis hints at 2018 outlook hike despite drug price freeze
RE
06:52pGLAXOSMITHKLINE : ViiV Healthcare shares data from landmark 2-drug regimen trial..
PU
06:51pNovartis hints at 2018 outlook hike despite drug price freeze
RE
11:38aCanSino latest to file for HKEX IPO
AQ
10:05aNOVARTIS : Backs 2018 Outlook, Says Cohen Affair Is 'Closed' -- Update
DJ
09:35aFetal gene therapy could treat neurodegenerative disease
AQ
07:46aNOVARTIS : Backs 2018 Outlook After Sales Grow
DJ
07/17GLAXOSMITHKLINE : FDA AdComm backs GlaxoSmithKlines one-shot P. vivax malaria th..
AQ
07/16GLAXOSMITHKLINE : Health and Human Services Department (HHS); Food and Drug Admi..
AQ
07/14GLAXOSMITHKLINE : James Ford Appointed GSK General Counsel
AQ
More news
News from SeekingAlpha
06:48aFDA OKs J&J's single tablet darunavir-based regimen for HIV-1 
07/17Gilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug 
07/16CVS responds to Trump Administration's request for info on now to lower drug .. 
07/15YOUR DAILY PHARMA SCOOP : Zogenix Zooms, Zynerba's Changing Fortunes, AbbVie Pro.. 
07/12Ad Com thumbs up on Glaxo's malaria drug tafenoquine; shares up 1.5% 
Financials (GBP)
Sales 2018 30 286 M
EBIT 2018 8 119 M
Net income 2018 3 884 M
Debt 2018 20 746 M
Yield 2018 5,13%
P/E ratio 2018 21,32
P/E ratio 2019 17,62
EV / Sales 2018 3,24x
EV / Sales 2019 3,12x
Capitalization 77 424 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 15,9  GBP
Spread / Average Target 1,7%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE18.03%101 396
JOHNSON & JOHNSON-10.76%346 292
PFIZER3.20%220 236
ROCHE HOLDING LTD.-5.88%200 995
NOVARTIS-5.10%200 139
MERCK AND COMPANY11.12%168 225